September 17, 2024

Jefferson Health Plans will start the annual Synagis® Prior Authorization process on October 16, 2024, two weeks before the respiratory syncytial virus (RSV) season begins. Synagis® (palivizumab) is a monoclonal antibody indicated to prevent a severe lower respiratory tract disease caused by RSV in infants and children at high risk. The RSV season begins November 1, 2024, and runs through March 31, 2025.